| 2016-02 |
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
Oncology Research and Treatment. 2016 Feb;39(Suppl. 1):170. |
 |
| 2016-02 |
A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC) |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract TPS482. |
|
| 2016-02 |
Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 417. |
|
| 2016-02 |
Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 134. |
|
| 2016-02 |
Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC) |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 369. |
|
| 2016-02 |
Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 745. |
|
| 2015-12 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma-TCOG 3211 clinical trial |
Journal of Gastroenterology and Hepatology. 2015 Dec;30(Suppl. S4):99. |
|
| 2015-09 |
The safety and efficacy of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan |
European Journal of Cancer. 2015 Sep;51(Suppl. 3):S459. |
|
| 2015-09 |
Expression of the Helicobater pylori CagA protein is closely associated with Helicobater pylori-dependence of early-stage high-grade gastric lymphoma |
European Journal of Cancer. 2015 Sep;51(Suppl. 3):S662. |
|
| 2015-08 |
The association between periodontal disease and pancreatic cancer |
Cancer Research. 2015 Aug;75:Abstract number 871. |
|
| 2015-05 |
Heterogeneous cell origin of helicobater pylori-dependent high-grade gastric lymphomas |
Journal of Clinical Oncology. 2015 May;33(15, Suppl.):e19520. |
|
| 2015-05 |
Randomized, phase III trial of adjuvant adeforvir vs. therapeutic lamivudine in post-operative BCLC stage 0 or A HBV-related HCC: The Taiwan Cooperative Oncology Group T1206 study |
Journal of Clinical Oncology. 2015 May;33(15, Suppl.):4101. |
|
| 2015-05 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial |
Journal of Clinical Oncology. 2015 May;33(15, Suppl.):4024. |
|
| 2015-01 |
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
Journal of Clinical Oncology. 2015 Jan;33(3, Suppl. ):234. |
|
| 2014-12 |
Pegylated arginine deiminase (ADI-PEG20) in relapsed/refractory and/or elder Acute Myeloid Leukemia: The preliminary result of phase II trial |
Blood. 2014 Dec;124(21):984. |
|
| 2014-10 |
Nuclear expression of BCL10 has a role in the regulation of cell growth and progression of pancreatic cancer through the activation of NF-kappa B-related signaling |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 4217. |
|
| 2014-05 |
Using chinese herbal medicine containing mu-tong is associated with upper urinary tract cancer in patient with end-stage renal disease |
Nephrology, Dialysis, Transplantation. 2014 May;29(Suppl. 3):iii65-iii67. |
|
| 2014-05 |
Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally ad |
Journal of Clinical Oncology. 2014 May;32(15, Suppl.):TPS4148. |
|
| 2014-05 |
Association of helicobacter pylori CagA translocation with the expression of CagA-signaling transduction molecules in gastric mucosa-associated lymphoid tissue lymphoma |
Journal of Clinical Oncology. 2014 May;32(15, Suppl.):8571. |
|
| 2014-05 |
High expression of Hsp90-beta and GRP 94 association with poor survival in resected non-small cell lung cancer patients |
Journal of Clinical Oncology. 2014 May;32(15, Suppl.):e13522. |
|
| 2014-05 |
A phase I dose escalation study of weekly BI 836845, a fully human, affinity-optineized, insulin -like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid cancers |
Journal of Clinical Oncology. 2014 May;32(15, Suppl.):2617. |
|
| 2014-01 |
EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib |
Journal of Clinical Oncology. 2014 Jan;32(3 Suppl.):Abstract number 172 |
|
| 2014-01 |
Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial |
Journal of Clinical Oncology. 2014 Jan;32(3 Suppl):Abstract number 267. |
|
| 2013-05 |
Effective treatment of aggressive B-cell lymphomas by downregulated NIK-induced noncanonical NF-kappa B pathway activation through inhibition of BAFF |
Journal of Clinical Oncology. 2013 May;31(15 Suppl.):Abstract number e13554. |
|
| 2013-05 |
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial |
Journal of Clinical Oncology. 2013 May;31(15 Suppl.):Abstract number 4018. |
|
| 2013-05 |
Impact of virologic factors on recurrence-free survival in HBV-related hepatocellular carcinoma after surgical resection: Post hoc analysis from a prospective study with long-term follow-up |
Journal of Clinical Oncology. 2013 May;31(15 Suppl.):Abstract number e15032. |
|
| 2013-03 |
Auy922, a novel Hsp90 inhibitor effective against ABC-dlbcl and malt lymphoma cells harboring genetic alteration-associated NF-kappa B activation |
Annals of Oncology. 2013 Mar;24(Suppl. 1):24-25. |
|
| 2012-11 |
Blockage of Nrf2/AKR1C axis enhanced therapeutic efficacy of oxaliplatin in oxaliplatin resistant gastric cancer cells |
European Journal of Cancer. 2012 Nov;48(Suppl. 6):48. |
|
| 2012-10 |
Front-line antibiotic therapy in early-stage H. Pylori-positive gastric Diffuse Large B-Cell Lymphomas with or without malt features |
Annals of Oncology. 2012 Oct;23(Suppl. 11):105. |
|
| 2012-09 |
Heat shock protein 90 inhibition downregulates c-Kit expression in gist cells through diminishing transcription and enhancing protein degradation via both autophagy and proteasome pathways |
Annals of Oncology. 2012 Sep;23(Suppl. 9):538. |
|
| 2012-09 |
Detection of caga expression in gastric mucosa-associated lymphoid tissue lymphoma-biologic significance and clinical implication |
Annals of Oncology. 2012 Sep;23(Suppl. 9):351. |
|
| 2012-05-20 |
Randomized phase II trial of TACE plus everolimus as first-line therapy in localized unresectable hepatocellular carcinoma (HCC): The TRACER trial |
Journal of Clinical Oncology. 2012 May 20;30(15 Suppl.):Abstract number TPS4149. |
|
| 2012-03 |
Involvement of autophagy in endogenous and NVP-AUY922-induced C-kit degradation in both imatinib-sensitive and -resistant gastrointestinal stromal tumor cells |
Annals of Oncology. 2012 Mar;23(Suppl. 1):28. |
|
| 2012-02 |
Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on firstline oxaliplatin-based chemotherapy |
Journal of Clinical Oncology. 2012 Feb;30(4):613. |
|
| 2011-11 |
Role of chromogranin a and neuron-specific enolase biomarkers in progression-free survival (PFS) with everolimus (EVE) versus placebo (PB) in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III radiant-3 results |
Neuroendocrinology. 2011 Nov;94(Suppl. 1):37. |
|
| 2011-09 |
B cell-activating factor of TNF family (BAFF) signaling pathway is associated with Helicobacter Pylori-independent growth of gastric MALT lymphoma without T(11;18)(q21;q21) |
European Journal of Cancer. 2011 Sep;47(Suppl 1):S648-S649. |
|
| 2011-09 |
Phase II study of low-dose everolimus plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for first-line treatment of metastatic or recurrent gastric cancers |
European Journal of Cancer. 2011 Sep;47(Suppl 1):S467. |
|
| 2011-05 |
Novel Hsp90 inhibitor NVP-AUY922 downregulates mutant c-Kit protein through transcription and enhancing protein degradation via both proteasome and autophagy-mediated pathways |
Drug Metabolism Reviews. 2011 May;43(Suppl. 1):78-79. |
|
| 2011-04 |
Activation of Akt/FoxO axis confers resistance to cisplatin in human nasopharyngeal carcinomas |
Cancer Research. 2011 Apr;71:Abstract number 1701. |
|
| 2011-02 |
Loss of ASS1 expression in myxofibrosarcoma via promoter hypermethylation: Prognostic and potential therapeutic implications |
Laboratory Investigation. 2011 Feb;91:17A. |
|
| 2011-02 |
Loss of ASS1 expression in myxofibrosarcoma via promoter hypermethylation: Prognostic and potential therapeutic implications |
Modern Pathology. 2011 Feb;24(Suppl. 1):17A-18A. |
|
| 2011-02 |
A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer |
Journal of Clinical Oncology. 2011 Feb;29(4):Abstract Number 237. |
|
| 2011-02 |
Phase II study of weekly low-dose everolimus plus weekly 24-hour infusions of cisplatin and high-dose 5-fluorouracil and leucovorin for first-line treatment in patients with advanced gastric cancers |
Journal of Clinical Oncology. 2011 Feb;29(4):Abstract Number 86. |
|
| 2011-02 |
Randomized phase II study of PEP02, irinotecan, or docetaxel as a second-line therapy in gastric or gastroesophageal junction adenocarcinoma |
Journal of Clinical Oncology. 2011 Feb;29(Suppl. 4 ):Abstract Number 6 |
|
| 2011-02 |
Effect of inhibition of heat-shock protein 90 on mutant c-Kit protein as modulated by mRNA expression and protein degradation through both proteasome and autophagy-mediated pathways |
Journal of Clinical Oncology. 2011 Feb;29(Suppl. 4):Abstract Number 54 |
|
| 2010-11 |
Medical resources utilization of five most prevalent cancers in Taiwan (lung cancer, liver cancer, colorectal cancer, gastric cancer, and brest cancer): 2001 similar to 2007 |
Value in Health. 2010 Nov;13(7):A279. |
|
| 2010-10 |
Nilotinib and sorafenib are more potent inhibitors for exon 11/17 C-kit mutants than sunitinib: results of incorporating cell-based screening platform and virtual molecular modeling study |
Annals of Oncology. 2010 Oct;21(Suppl. 8):56-56. |
|
| 2010-10 |
Combined modalities of resistance in a cisplatin-driven human betel-associated oral squamous cell carcinoma |
Annals of Oncology. 2010 Oct;21(Suppl. 8):52. |
|
| 2010-06 |
Randomized, phase 1 study of everolimus in patients with advanced hepatocellular carcinoma |
Annals of Oncology. 2010 Jun;21(Suppl. 6):27. |
|
| 2010-05 |
Phase I study of liposome irinotecan (PEP02) in combination with weekly infusion of 5-FU/LV in advanced solid tumors |
Journal of Clinical Oncology. 2010 May;28(15):Abstract Number e13024. |
|
